#Fort Lauderdale #FDA Clearance #Anovo System #Momentis Surgical

Momentis Surgical's Anovo System Receives FDA Clearance for Multiport Surgery

Momentis Surgical has taken a significant stride in the field of robotic surgery with the recent 510(k) clearance granted by the U.S. Food and Drug Administration (FDA) for the multiport configuration of the Anovo® Surgical System. This landmark approval positions Anovo as the pioneering robotic platform capable of supporting three distinct surgical approaches—natural orifice, single-port, and multiport—within a single, innovative system.

The Anovo Surgical System’s versatility is revolutionary, allowing surgeons to choose the most suitable surgical method tailored to each patient's needs without the hassle of managing multiple different robotic systems. The platform enables the use of proprietary, internally articulated instruments inspired by the dexterity of human anatomy, specifically designed to enhance surgical precision and flexibility.

With multiport surgery now integrated into the Anovo system, surgeons can seamlessly use its advanced instruments to perform various minimally invasive procedures. This includes the potential for general surgeons to tackle ventral hernia repair through single-site or multiport methods and provides gynecologists the option to incorporate multiport approaches into their transvaginal operations.

Dvir Cohen, the CEO of Momentis Surgical, emphasized the company's aim from day one to rethink robotic surgery comprehensively.